Cancer cell proteins and cervical cancer return risk
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial looks at whether certain proteins that stop cell death (called inhibitor of apoptosis proteins) in cervical cancer tissue can help predict if the cancer will come back after treatment. It studies patients who had chemoradiation for advanced cervical cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had chemoradiation as your only treatment for locally advanced cervical cancer (stages 1b to 4b).
- You are 18 years or older.
- You have been followed for at least 2 years after your treatment ended.
- A sample of your cancer taken before treatment is still available for testing.
- You are willing to let the researchers use your medical information and samples.
- You have health insurance.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests cadonilimab (an immunotherapy) combined with nab-paclitaxel (chemo) to treat cervical cancer that has come back or spread and did not respond to prior immune checkpoint medicines. It may help shrink tumors and improve disease control after prior immunotherapy failure.
This study follows patients with cervical cancer caused by HPV (a common virus) who receive radiation and chemotherapy together. Researchers will track whether the HPV virus stays in the body after treatment and how this affects long-term outcomes.
This trial is testing a special blood test (called personalized ctDNA MRD) to see if it can give early warning about cancer returning after treatment. If you have cervical cancer that can be treated with surgery or chemoradiation, and you haven't had treatment yet, you may be eligible.
This trial tests a combination of three types of cancer-fighting drugs—an immunotherapy (camrelizumab), a targeted therapy (famitinib), and chemotherapy—to treat cervical cancer that has returned or spread. The goal is to see if this combination works better than standard treatment.
This study looks at whether certain markers in your blood (DNA from cancer cells and HPV) can help predict how well you do after first treatment for cervical cancer that has come back or spread. You would have extra blood draws during follow-up visits.
This Phase 3 study tests whether giving additional (adjuvant) chemotherapy after standard chemoradiation can help people whose blood test still shows cancer-related HPV DNA. It may help by lowering the risk of the cervical cancer coming back in people who have a positive blood biomarker after treatment.
Hear when a new Cancer of Cervix trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.